FDA Suggests Gene Therapy Data May Support Accelerated Approval for Huntington Disease

The FDA has informed uniQure that its 3-year Phase 1/2 data for the investigational gene therapy AMT-130 for Huntington disease could form the basis for an accelerated approval submission. The company plans to submit a Biologics License Application in Q3 2026, based on high-dose AMT-130 showing a 75% slowing of disease progression. The FDA's guidance also suggests a confirmatory trial might not require a sham neurosurgical control.

Context

Huntington disease is a progressive neurodegenerative disorder that affects movement, cognition, and behavior. Current treatments primarily focus on managing symptoms rather than halting disease progression. uniQure's AMT-130 is an investigational gene therapy that aims to target the underlying cause of the disease. The recent Phase 1/2 trial results showing a 75% slowing of progression are promising and have prompted the FDA's interest.

Why it matters

The FDA's indication that gene therapy data may support accelerated approval for Huntington disease is significant as it could lead to faster access to potentially life-changing treatments. Huntington disease currently has no cure, and advancements in gene therapy could alter the course of the disease for patients. This development reflects the FDA's willingness to expedite the approval process for therapies addressing serious conditions.

Implications

If AMT-130 receives accelerated approval, it could provide a new treatment option for patients with Huntington disease, potentially improving their quality of life. The approval may also encourage further investment in gene therapies for other neurodegenerative diseases. Patients and families affected by Huntington disease will be particularly impacted, as they may gain access to innovative treatments sooner than anticipated.

What to watch

uniQure plans to submit a Biologics License Application in the third quarter of 2026, which will be a key milestone in the approval process. The FDA's suggestion that a confirmatory trial may not require a sham neurosurgical control could streamline the development timeline. Observers should monitor any updates from uniQure regarding trial results and regulatory communications leading up to the application submission.